PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers

This checklist is intended as an aid to support clinical decision making for prescribers. However, use of this checklist is not required to prescribe PAXLOVID under the EUA.

Medical History

- Positive SARS-CoV-2 test (Confirmation of a positive home rapid SARS-CoV-2 test result with additional direct SARS-CoV-2 viral testing is not required.)
- Age ≥ 18 years OR > 12 years of age and weighing at least 40 kg
- Has one or more risk factors for progression to severe COVID-19\(^1\) (Healthcare providers should consider the benefit-risk for an individual patient.)
- Symptoms consistent with mild to moderate COVID-19\(^2\)
- Symptom onset within 5 days (Prescriber is encouraged to include a note to the pharmacist in the prescription stating: Please fill prescription by [insert date]. This prescription fill by date is within 5 days from symptom onset and complies with the patient eligibility criteria under the EUA.)
- Not requiring hospitalization due to severe or critical COVID-19 at treatment initiation
- No known or suspected severe renal impairment (eGFR < 30 mL/min)
  - Note that a dose reduction is required for patients with moderate renal impairment (eGFR ≥ 30-<60 mL/min); see the Fact Sheet for Healthcare Providers.
  - Prescriber may rely on patient history and access to the patient’s health records to make an assessment regarding the likelihood of renal impairment. Providers may consider ordering a serum creatinine or calculating the estimated glomerular filtration rate (eGFR) for certain patients after assessment on a case-by-case basis based on history or exam.
- No known or suspected severe hepatic impairment (Child-Pugh Class C)
- No history of clinically significant hypersensitivity reactions [e.g., toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome] to the active ingredients (nirmatrelvir or ritonavir) or other components of the product

NOTES: __________________________________________________________

Concomitant Medications

- HMG-CoA reductase inhibitors (statins)
  - If the patient is taking lovastatin or simvastatin, which are contraindicated with PAXLOVID coadministration, PAXLOVID can be given if the statin can be held 12 hours prior to the first dose of PAXLOVID treatment, held during the 5 days of treatment, and restarted 5 days after completing PAXLOVID.
  - If the patient is taking atorvastatin or rosuvastatin, consider temporary discontinuation of atorvastatin and rosuvastatin during treatment with

---

\(^2\) [https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/#:~:text=Patients%20with%20mild%20illness%20may,on%20exertion%20%2C%20or%20abnormal%20imaging](https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/#:~:text=Patients%20with%20mild%20illness%20may,on%20exertion%20%2C%20or%20abnormal%20imaging)
PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers

PAXLOVID. Atorvastatin and rosuvastatin do not need to be held prior to or after completing PAXLOVID.

- **Hormonal contraceptives containing ethinyl estradiol:** If the patient is taking a hormonal contraceptive containing ethinyl estradiol, consider an additional non-hormonal method of contraception during the 5 days of PAXLOVID treatment and until one menstrual cycle after stopping PAXLOVID.

- **Medications for HIV-1 Treatment:** If the patient is taking medications for the treatment of HIV-1 infection, with the exception of maraviroc, HIV antiretroviral medications can be co-administered with PAXLOVID without dose adjustment, but arranging follow-up by the HIV care provider to monitor for side effects is recommended.

- **Other Drugs with Established and Other Potentially Significant Drug Interactions with PAXLOVID**
  - Patient is not taking any other medications
  - Patient is not taking any of the medications listed below.
    - In addition, the patient’s other medications have been checked for contraindications, the need for dose adjustment, or increased monitoring due to drug interactions with a strong CYP3A inhibitor such as ritonavir based on appropriate resources such as the prescribing information of these medications.
  - Patient is NOT taking any of the medications listed in RED but is taking one or more of the medications listed below in YELLOW, and dose adjustment, holding of medication, or increased monitoring is planned (additional resources which include instructions for managing specific drug interactions are included at the end of this document).
    - In addition, the patient’s other medications not listed below have been checked for contraindications, the need for dose adjustment, or increased monitoring due to drug interactions with a strong CYP3A inhibitor such as ritonavir based on appropriate resources such as the prescribing information of these medications.

NOTES: ____________________________________________________________

---

3 Please see the maraviroc prescribing information here: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022128Orig1s019,208984Orig1s002lbl.pdf

4 Exposure of certain HIV medications may be altered with PAXLOVID co-administration.

5 Patients on ritonavir- or cobicistat-containing HIV or HCV regimens should continue their treatment as indicated.

6 PAXLOVID use may lead to a risk of HIV-1 developing resistance to HIV protease inhibitors in individuals with uncontrolled or undiagnosed HIV-1 infection.
Other Drugs with Established and Other Potentially Significant Drug Interactions with PAXLOVID (listed alphabetically by generic name)

Interaction Codes:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Drug Class</th>
<th>Interaction Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>abemaciclib</td>
<td>Anticancer drug</td>
<td>***</td>
</tr>
<tr>
<td>alfuzosin</td>
<td>Alpha 1-adrenoreceptor antagonist</td>
<td>XXX</td>
</tr>
<tr>
<td>amiodarone</td>
<td>Antiarrhythmic</td>
<td>XXX</td>
</tr>
<tr>
<td>amlodipine</td>
<td>Calcium channel blocker</td>
<td>***</td>
</tr>
<tr>
<td>apalutamide</td>
<td>Anticancer drug</td>
<td>XXX</td>
</tr>
<tr>
<td>bedaquiline</td>
<td>Antimycobacterial</td>
<td>***</td>
</tr>
<tr>
<td>bepridil</td>
<td>Antiarrhythmic</td>
<td>***</td>
</tr>
<tr>
<td>betamethasone</td>
<td>Systemic corticosteroid</td>
<td>***</td>
</tr>
<tr>
<td>bosentan</td>
<td>Endothelin receptor antagonist</td>
<td>***</td>
</tr>
<tr>
<td>budesonide</td>
<td>Systemic corticosteroid</td>
<td>***</td>
</tr>
<tr>
<td>bupropion</td>
<td>Antidepressant</td>
<td>***</td>
</tr>
<tr>
<td>carbamazepine</td>
<td>Anticonvulsant</td>
<td>XXX</td>
</tr>
<tr>
<td>ceritinib</td>
<td>Anticancer drug</td>
<td>***</td>
</tr>
<tr>
<td>ciclesonide</td>
<td>Systemic corticosteroid</td>
<td>***</td>
</tr>
</tbody>
</table>

The table below provides a listing of clinically significant drug interactions, including contraindicated drugs, in addition to those listed under Concomitant Medications above (HMG-CoA reductase inhibitors [statins], hormonal contraceptives containing ethinyl estradiol, and medications for HIV-1 treatment). Drugs listed in this table are a guide and are not considered a comprehensive list of all possible drugs that may interact with PAXLOVID. The healthcare provider should consult other appropriate resources such as the prescribing information for the interacting drug for comprehensive information on dosing or monitoring with concomitant use of a strong CYP3A inhibitor such as ritonavir.
## PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers

<table>
<thead>
<tr>
<th>Drug</th>
<th>Drug Class</th>
<th>Interaction Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>clarithromycin</td>
<td>Anti-infective</td>
<td>***</td>
</tr>
<tr>
<td>clozapine</td>
<td>Antipsychotic</td>
<td>XXX</td>
</tr>
<tr>
<td>colchicine</td>
<td>Anti-gout</td>
<td>XXX</td>
</tr>
<tr>
<td>cyclosporine</td>
<td>Immunosuppressant</td>
<td>***</td>
</tr>
<tr>
<td>dabigatran</td>
<td>Anticoagulants</td>
<td>***</td>
</tr>
<tr>
<td>dasabuvir</td>
<td>Hepatitis C direct acting antiviral</td>
<td>***</td>
</tr>
<tr>
<td>dasatinib</td>
<td>Anticancer drug</td>
<td>***</td>
</tr>
<tr>
<td>dexamethasone</td>
<td>Systemic corticosteroid</td>
<td>***</td>
</tr>
<tr>
<td>digoxin</td>
<td>Cardiac glycoside</td>
<td>***</td>
</tr>
<tr>
<td>dihydroergotamine</td>
<td>Ergot derivative</td>
<td>XXX</td>
</tr>
<tr>
<td>diltiazem</td>
<td>Calcium channel blocker</td>
<td>***</td>
</tr>
<tr>
<td>dronedarone</td>
<td>Antiarhythmic</td>
<td>XXX</td>
</tr>
<tr>
<td>elbasvir/grazoprevir</td>
<td>Hepatitis C direct acting antiviral</td>
<td>***</td>
</tr>
<tr>
<td>encorafenib</td>
<td>Anticancer drug</td>
<td>***</td>
</tr>
<tr>
<td>ergotamine</td>
<td>Ergot derivative</td>
<td>XXX</td>
</tr>
<tr>
<td>erythromycin</td>
<td>Anti-infective</td>
<td>***</td>
</tr>
<tr>
<td>felodipine</td>
<td>Calcium channel blocker</td>
<td>***</td>
</tr>
<tr>
<td>fentanyl</td>
<td>Narcotic analgesic</td>
<td>***</td>
</tr>
<tr>
<td>flecainide</td>
<td>Antiarrhythmic</td>
<td>XXX</td>
</tr>
<tr>
<td>fluticasone</td>
<td>Systemic corticosteroid</td>
<td>***</td>
</tr>
<tr>
<td>glecaprevir/pibrentasvir</td>
<td>Hepatitis C direct acting antiviral</td>
<td>***</td>
</tr>
<tr>
<td>ibrutinib</td>
<td>Anticancer drug</td>
<td>***</td>
</tr>
<tr>
<td>isavuconazonium sulfate</td>
<td>Antifungal</td>
<td>***</td>
</tr>
<tr>
<td>itraconazole</td>
<td>Antifungal</td>
<td>***</td>
</tr>
<tr>
<td>ivosidenib</td>
<td>Anticancer drug</td>
<td>***</td>
</tr>
<tr>
<td>ketoconazole</td>
<td>Antifungal</td>
<td>***</td>
</tr>
<tr>
<td>lidocaine (systemic)</td>
<td>Antiarhythmic</td>
<td>***</td>
</tr>
<tr>
<td>lurasidone</td>
<td>Antipsychotic</td>
<td>XXX</td>
</tr>
<tr>
<td>methadone</td>
<td>Narcotic analgesic</td>
<td>***</td>
</tr>
<tr>
<td>methylergonovine</td>
<td>Ergot derivative</td>
<td>XXX</td>
</tr>
<tr>
<td>methylprednisolone</td>
<td>Systemic corticosteroid</td>
<td>***</td>
</tr>
<tr>
<td>midazolam (administered parentally)</td>
<td>Sedative/hypnotic</td>
<td>***</td>
</tr>
<tr>
<td>midazolam (oral)</td>
<td>Sedative/hypnotic</td>
<td>XXX</td>
</tr>
<tr>
<td>mometasone</td>
<td>Systemic corticosteroid</td>
<td>***</td>
</tr>
<tr>
<td>neratinib</td>
<td>Anticancer drug</td>
<td>***</td>
</tr>
<tr>
<td>nicardipine</td>
<td>Calcium channel blocker</td>
<td>***</td>
</tr>
<tr>
<td>nifedipine</td>
<td>Calcium channel blocker</td>
<td>***</td>
</tr>
<tr>
<td>nilotinib</td>
<td>Anticancer drug</td>
<td>***</td>
</tr>
<tr>
<td>ombitasvir/paritaprevir/ritonavir</td>
<td>Hepatitis C direct acting antiviral</td>
<td>***</td>
</tr>
<tr>
<td>pethidine</td>
<td>Analgesic</td>
<td>XXX</td>
</tr>
<tr>
<td>phenobarbital</td>
<td>Anticonvulsant</td>
<td>XXX</td>
</tr>
</tbody>
</table>
# PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers

<table>
<thead>
<tr>
<th>Drug</th>
<th>Drug Class</th>
<th>Interaction Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>phenytoin</td>
<td>Anticonvulsant</td>
<td>XXX</td>
</tr>
<tr>
<td>pimozide</td>
<td>Antipsychotic</td>
<td>XXX</td>
</tr>
<tr>
<td>prednisone</td>
<td>Systemic corticosteroid</td>
<td>***</td>
</tr>
<tr>
<td>propafenone</td>
<td>Antiarrhythmic</td>
<td>XXX</td>
</tr>
<tr>
<td>propoxyphene</td>
<td>Analgesic</td>
<td>XXX</td>
</tr>
<tr>
<td>quetiapine</td>
<td>Antipsychotic</td>
<td>***</td>
</tr>
<tr>
<td>quinidine</td>
<td>Antiarrhythmic</td>
<td>XXX</td>
</tr>
<tr>
<td>ranolazine</td>
<td>Antianginal</td>
<td>XXX</td>
</tr>
<tr>
<td>rifabutin</td>
<td>Antimycobacterial</td>
<td>***</td>
</tr>
<tr>
<td>rifampin</td>
<td>Antimycobacterial</td>
<td>XXX</td>
</tr>
<tr>
<td>rivaroxaban</td>
<td>Anticoagulant</td>
<td>***</td>
</tr>
<tr>
<td>salmeterol</td>
<td>Long-acting beta-adrenoceptor agonist</td>
<td>***</td>
</tr>
<tr>
<td>sildenafil (Revatio®) when used for pulmonary arterial hypertension</td>
<td>PDE5 inhibitor</td>
<td>XXX</td>
</tr>
<tr>
<td>sirolimus</td>
<td>Immunosuppressant</td>
<td>***</td>
</tr>
<tr>
<td>sofosbuvir/velpatasvir/ voxilaprevir</td>
<td>Hepatitis C direct acting antiviral</td>
<td>***</td>
</tr>
<tr>
<td>St. John’s Wort (hypericum perforatum)</td>
<td>Herbal product</td>
<td>XXX</td>
</tr>
<tr>
<td>tacrolimus</td>
<td>Immunosuppressant</td>
<td>***</td>
</tr>
<tr>
<td>trazodone</td>
<td>Antidepressant</td>
<td>***</td>
</tr>
<tr>
<td>triamcinolone</td>
<td>Systemic corticosteroid</td>
<td>***</td>
</tr>
<tr>
<td>triazolam</td>
<td>Sedative/hypnotic</td>
<td>XXX</td>
</tr>
<tr>
<td>venetoclax</td>
<td>Anticancer drug</td>
<td>***</td>
</tr>
<tr>
<td>vinblastine</td>
<td>Anticancer drug</td>
<td>***</td>
</tr>
<tr>
<td>vincristine</td>
<td>Anticancer drug</td>
<td>***</td>
</tr>
<tr>
<td>voriconazole</td>
<td>Antifungal</td>
<td>***</td>
</tr>
<tr>
<td>warfarin</td>
<td>Anticoagulant</td>
<td>***</td>
</tr>
</tbody>
</table>

**ADDITIONAL RESOURCES:**


Prescribing Information (Label/Package Insert) for Individual Drugs (Drugs@FDA): [https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm)

University of Liverpool COVID-19 Drug Interactions: [https://www.covid19-druginteractions.org/checker](https://www.covid19-druginteractions.org/checker)


---

Page | 5  
6/3/2022